We recently compiled a list of the 11 Oversold Blue Chip Stocks to Buy According to Hedge Funds. In this article, we are ...

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm ...

Wen is among the 40 finalists heading to Washington, D.C., Thursday to present their projects to panels of experts. The ...

The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...

A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for review the resubmission of the ...

Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

Regeneron last year won European Commission approval of odronextamab as Ordspono for relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma after two or more lines of systemic ...

The successful development of these oncology drugs should be a great boost for REGN. Last month, Regeneron reported better-than-expected results for the fourth quarter, but the decline in lead ...